Bioventus Inc. (NYSE:BVS) CFO Sells $29,333.75 in Stock

Bioventus Inc. (NYSE:BVS - Get Free Report) CFO Mark Leonard Singleton sold 3,875 shares of the business's stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $7.57, for a total value of $29,333.75. Following the completion of the transaction, the chief financial officer now owns 141,088 shares in the company, valued at $1,068,036.16. This trade represents a 2.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mark Leonard Singleton also recently made the following trade(s):

• On Monday, March 24th, Mark Leonard Singleton sold 5,479 shares of Bioventus stock. The stock was sold at an average price of $9.79, for a total value of $53,639.41.
• On Tuesday, February 18th, Mark Leonard Singleton sold 6,498 shares of Bioventus stock. The stock was sold at an average price of $10.19, for a total transaction of $66,214.62.

Bioventus Price Performance

BVS traded up $0.04 on Friday, hitting $7.82. 323,591 shares of the company were exchanged, compared to its average volume of 446,547. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The firm has a market capitalization of $640.80 million, a P/E ratio of -12.82 and a beta of 0.92. The business's fifty day moving average is $9.29 and its 200 day moving average is $10.60.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Bioventus in a report on Monday, March 17th.

Hedge Funds Weigh In On Bioventus

Several hedge funds have recently bought and sold shares of BVS. Tower Research Capital LLC TRC grew its holdings in Bioventus by 106.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company's stock valued at $36,000 after purchasing an additional 1,786 shares during the last quarter. Plato Investment Management Ltd purchased a new stake in shares of Bioventus in the 4th quarter worth about $38,000. GAMMA Investing LLC boosted its position in shares of Bioventus by 3,228.7% in the 1st quarter. GAMMA Investing LLC now owns 5,792 shares of the company's stock worth $53,000 after buying an additional 5,618 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Bioventus in the 4th quarter valued at about $75,000. Finally, Quantbot Technologies LP purchased a new position in Bioventus during the 4th quarter valued at about $103,000. 62.94% of the stock is owned by hedge funds and other institutional investors.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.